uniQure (NASDAQ:QURE) Shares Up 6.3% – Still a Buy?

uniQure N.V. (NASDAQ:QURE)’s stock price shot up 6.3% during trading on Monday . The company traded as high as $20.05 and last traded at $20.3370. 129,852 shares were traded during trading, a decline of 95% from the average session volume of 2,831,731 shares. The stock had previously closed at $19.13.

Analysts Set New Price Targets

A number of research firms have commented on QURE. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Leerink Partners reaffirmed an “outperform” rating and set a $35.00 target price on shares of uniQure in a report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a report on Wednesday, January 21st. Barclays cut their price target on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a report on Monday, March 23rd. Finally, Stifel Nicolaus set a $14.00 price target on uniQure in a report on Monday, March 2nd. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, uniQure currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.33.

uniQure Stock Performance

The stock has a market cap of $1.30 billion, a P/E ratio of -5.96 and a beta of 0.87. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43. The company has a fifty day moving average of $16.75 and a 200 day moving average of $25.53.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The firm had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. On average, equities analysts predict that uniQure N.V. will post -3.6 earnings per share for the current fiscal year.

Insider Transactions at uniQure

In other news, CFO Christian Klemt sold 12,000 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $108,720.00. Following the sale, the chief financial officer owned 226,581 shares of the company’s stock, valued at approximately $2,052,823.86. The trade was a 5.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jeannette Potts sold 3,412 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the sale, the insider directly owned 138,483 shares in the company, valued at $1,254,655.98. This represents a 2.40% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 49,396 shares of company stock valued at $722,734. Corporate insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Torren Management LLC acquired a new stake in shares of uniQure during the fourth quarter worth approximately $28,000. Jones Financial Companies Lllp boosted its holdings in shares of uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the period. IFP Advisors Inc acquired a new stake in shares of uniQure during the fourth quarter worth approximately $48,000. Smartleaf Asset Management LLC acquired a new stake in shares of uniQure during the fourth quarter worth approximately $48,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in shares of uniQure during the third quarter worth approximately $50,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.